The estimated Net Worth of Michael Kharitonov is at least $2.26 millió dollars as of 23 March 2016. Michael Kharitonov owns over 900,000 units of Heat Biologics Inc stock worth over $2,260,905 and over the last 11 years Michael sold HTBX stock worth over $0.
Michael has made over 2 trades of the Heat Biologics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Michael bought 900,000 units of HTBX stock worth $675,000 on 23 March 2016.
The largest trade Michael's ever made was buying 900,000 units of Heat Biologics Inc stock on 23 March 2016 worth over $675,000. On average, Michael trades about 360,000 units every 0 days since 2013. As of 23 March 2016 Michael still owns at least 949,960 units of Heat Biologics Inc stock.
You can see the complete history of Michael Kharitonov stock trades at the bottom of the page.
Michael's mailing address filed with the SEC is C/O 100 EUROPA DRIVE, , CHAPEL HILL, NC, 27517.
Over the last 11 years, insiders at Heat Biologics Inc have traded over $311,853 worth of Heat Biologics Inc stock and bought 1,805,692 units worth $1,373,576 . The most active insiders traders include Louis C Bock, Michael Kharitonov és John K A Prendergast. On average, Heat Biologics Inc executives and independent directors trade stock every 319 days with the average trade being worth of $582,988. The most recent stock trade was executed by John K A Prendergast on 14 May 2021, trading 35,000 units of HTBX stock currently worth $205,450.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
Heat Biologics Inc executives and other stock owners filed with the SEC include: